Pak2 siRNA/shRNA/RNAi
To Order Contact us: lieven@wlsolutions.be
) PAK2 siRNA (Rat) |
||
| MBS828816-5x30nmol | 5x30nmol | EUR 2450 |
 Mouse PAK2 siRNA |
||
| 20-abx927644 |
|
|
 Human PAK2 siRNA |
||
| 20-abx903828 |
|
|
) PAK2 siRNA (Mouse) |
||
| MBS8235582-15nmol | 15nmol | EUR 405 |
PAK2 siRNA (Mouse) |
||
| MBS8235582-30nmol | 30nmol | EUR 565 |
PAK2 siRNA (Mouse) |
||
| MBS8235582-5x30nmol | 5x30nmol | EUR 2450 |
) PAK2 siRNA (Human) |
||
| MBS8209993-15nmol | 15nmol | EUR 405 |
PAK2 siRNA (Human) |
||
| MBS8209993-30nmol | 30nmol | EUR 565 |
PAK2 siRNA (Human) |
||
| MBS8209993-5x30nmol | 5x30nmol | EUR 2450 |
 Rat PAK2 shRNA Plasmid |
||
| 20-abx985494 |
|
|
 Human PAK2 shRNA Plasmid |
||
| 20-abx953363 |
|
|
 Mouse PAK2 shRNA Plasmid |
||
| 20-abx981322 |
|
|
 - 3 unique 27mer siRNA duplexes - 2 nmol each) PAK2 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each |
||
| SR303348 | 2 nmol | Ask for price |
 - 3 unique 27mer siRNA duplexes - 2 nmol each) Pak2 (Mouse) - 3 unique 27mer siRNA duplexes - 2 nmol each |
||
| SR416668 | 2 nmol | Ask for price |
 pROKII- RNAI Plasmid |
||
| PVT3202 | 2 ug | EUR 319.2 |
 Pak2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
||
| TL711746 | 5 µg/vial | Ask for price |
 PAK2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
||
| TL320443 | 5 µg/vial | Ask for price |
 Pak2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
||
| TL506650 | 5 µg/vial | Ask for price |
 PAK2 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector |
||
| TF320443 | 5 µg/vial | Ask for price |
 Pak2 - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector |
||
| TR711746 | 5 µg/vial | Ask for price |
 PAK2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
||
| TR320443 | 5 µg/vial | Ask for price |
 Pak2 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector |
||
| TR506650 | 5 µg/vial | Ask for price |
 HighYield T7 RNAi Kit |
||
| RNT-134 | 50reactions x 20 µl | EUR 200.34 |
 T7 RNAi Transcription Kit |
||
| TR102-01 | 25 rxn | EUR 111.64 |
T7 RNAi Transcription Kit |
||
| TR102-01-25rxns | 25 rxns | EUR 115.61 |
T7 RNAi Transcription Kit |
||
| TR102-02 | 50 rxn | EUR 217.5 |
T7 RNAi Transcription Kit |
||
| TR102-02-50rxns | 50 rxns | EUR 225.22 |
 RNAi-Ready pSIREN-RetroQ |
||
| PVTY01204 | 2ug | EUR 280 |
 GeneGlide? RNAi Delivery Control |
||
| M1082-10 | each | EUR 284.4 |
GeneGlide? RNAi Delivery Control |
||
| M1082-100 | each | EUR 1002 |
GeneGlide? RNAi Delivery Control |
||
| M1082-50 | each | EUR 594 |
 Pak2/ Rat Pak2 ELISA Kit |
||
| ELI-22010r | 96 Tests | EUR 1063.2 |
, 0.5 ml each, >10^7 TU/ml.) PAK2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
||
| TL320443V | 500 ul each | Ask for price |
, 0.5 ml each, >10^7 TU/ml.) Pak2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
||
| TL506650V | 500 ul each | Ask for price |
, 0.5 ml each, >10^7 TU/ml.) Pak2 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
||
| TL711746V | 500 ul each | Ask for price |
 PAK2 |
||
| 40073 | 10 µg | EUR 495 |
|
Description: Human PAK2 (GenBank Accession No. NM_002577), a.a. 227-524, MW=33.5 kDa, expressed in E. coli. |
||
PAK2 |
||
| CSB-CL622641HU | 10 μg plasmid + 200μl Glycerol | Ask for price |
PAK2 |
||
| E8ET7107-79 | 100ul | EUR 275 |
|
Description: Available in various conjugation types. |
||
PAK2 |
||
| MBS9125968-002mL | 0.02mL | EUR 200 |
PAK2 |
||
| MBS9125968-005mL | 0.05mL | EUR 255 |
PAK2 |
||
| MBS9125968-01mL | 0.1mL | EUR 345 |
PAK2 |
||
| MBS9125968-02mL | 0.2mL | EUR 545 |
PAK2 |
||
| MBS9125968-5x02mL | 5x0.2mL | EUR 2265 |
PAK2 |
||
| MBS8565808-01mL | 0.1mL | EUR 345 |
PAK2 |
||
| MBS8565808-01mLAF405L | 0.1mL(AF405L) | EUR 565 |
PAK2 |
||
| MBS8565808-01mLAF405S | 0.1mL(AF405S) | EUR 565 |
PAK2 |
||
| MBS8565808-01mLAF610 | 0.1mL(AF610) | EUR 565 |
PAK2 |
||
| MBS8565808-01mLAF635 | 0.1mL(AF635) | EUR 565 |
PAK2 |
||
| MBS8562309-01mLAF405L | 0.1mL(AF405L) | EUR 565 |
PAK2 |
||
| MBS8562309-01mLAF405S | 0.1mL(AF405S) | EUR 565 |
PAK2 |
||
| MBS8562309-01mLAF610 | 0.1mL(AF610) | EUR 565 |
PAK2 |
||
| MBS8562309-01mLAF635 | 0.1mL(AF635) | EUR 565 |
PAK2 |
||
| MBS8562309-02mL | 0.2mL | EUR 345 |
 RNAi-Ready pSIREN-RetroQ-ZsGreen |
||
| PVTY01206 | 2ug | EUR 280 |
 RNAi-Ready pSIREN-RetroQ-ZsGreen1 |
||
| PVTY00817 | 2ug | EUR 280 |
 Rat PAK1 siRNA |
||
| 20-abx927641 |
|
|
 Rat PAK3 siRNA |
||
| 20-abx927645 |
|
|
 Rat PAK7 siRNA |
||
| 20-abx927651 |
|
|
) PAK7 siRNA (Rat) |
||
| MBS8225486-15nmol | 15nmol | EUR 405 |
PAK7 siRNA (Rat) |
||
| MBS8225486-30nmol | 30nmol | EUR 565 |
PAK7 siRNA (Rat) |
||
| MBS8225486-5x30nmol | 5x30nmol | EUR 2450 |
) PAK3 siRNA (Rat) |
||
| MBS8219486-15nmol | 15nmol | EUR 405 |
PAK3 siRNA (Rat) |
||
| MBS8219486-30nmol | 30nmol | EUR 565 |
PAK3 siRNA (Rat) |
||
| MBS8219486-5x30nmol | 5x30nmol | EUR 2450 |
) PAK1 siRNA (Rat) |
||
| MBS8230957-15nmol | 15nmol | EUR 405 |
PAK1 siRNA (Rat) |
||
| MBS8230957-30nmol | 30nmol | EUR 565 |
PAK1 siRNA (Rat) |
||
| MBS8230957-5x30nmol | 5x30nmol | EUR 2450 |
 Human PAK1 siRNA |
||
| 20-abx927642 |
|
|
 Mouse PAK3 siRNA |
||
| 20-abx927646 |
|
|
 Mouse PAK4 siRNA |
||
| 20-abx927647 |
|
|
 Human PAK4 siRNA |
||
| 20-abx927648 |
|
|
 Mouse PAK6 siRNA |
||
| 20-abx927649 |
|
|
 Human PAK6 siRNA |
||
| 20-abx927650 |
|
|
 Mouse PAK7 siRNA |
||
| 20-abx927652 |
|
|
 Human PAK3 siRNA |
||
| 20-abx903829 |
|
|
 Human PAK7 siRNA |
||
| 20-abx903830 |
|
|
) PAK1 siRNA (Human) |
||
| MBS8207508-15nmol | 15nmol | EUR 405 |
PAK1 siRNA (Human) |
||
| MBS8207508-30nmol | 30nmol | EUR 565 |
PAK1 siRNA (Human) |
||
| MBS8207508-5x30nmol | 5x30nmol | EUR 2450 |
) PAK4 siRNA (Human) |
||
| MBS8229054-15nmol | 15nmol | EUR 405 |
PAK4 siRNA (Human) |
||
| MBS8229054-30nmol | 30nmol | EUR 565 |
PAK4 siRNA (Human) |
||
| MBS8229054-5x30nmol | 5x30nmol | EUR 2450 |
) PAK6 siRNA (Mouse) |
||
| MBS8230838-15nmol | 15nmol | EUR 405 |
PAK6 siRNA (Mouse) |
||
| MBS8230838-30nmol | 30nmol | EUR 565 |
PAK6 siRNA (Mouse) |
||
| MBS8230838-5x30nmol | 5x30nmol | EUR 2450 |
) PAK7 siRNA (Human) |
||
| MBS8205597-15nmol | 15nmol | EUR 405 |
PAK7 siRNA (Human) |
||
| MBS8205597-30nmol | 30nmol | EUR 565 |
PAK7 siRNA (Human) |
||
| MBS8205597-5x30nmol | 5x30nmol | EUR 2450 |
) PAK6 siRNA (Human) |
||
| MBS8210259-15nmol | 15nmol | EUR 405 |
PAK6 siRNA (Human) |
||
| MBS8210259-30nmol | 30nmol | EUR 565 |
PAK6 siRNA (Human) |
||
| MBS8210259-5x30nmol | 5x30nmol | EUR 2450 |
) PAK7 siRNA (Mouse) |
||
| MBS8210366-15nmol | 15nmol | EUR 405 |
PAK7 siRNA (Mouse) |
||
| MBS8210366-30nmol | 30nmol | EUR 565 |
PAK7 siRNA (Mouse) |
||
| MBS8210366-5x30nmol | 5x30nmol | EUR 2450 |
) PAK3 siRNA (Mouse) |
||
| MBS8212208-15nmol | 15nmol | EUR 405 |
PAK3 siRNA (Mouse) |
||
| MBS8212208-30nmol | 30nmol | EUR 565 |
PAK3 siRNA (Mouse) |
||
| MBS8212208-5x30nmol | 5x30nmol | EUR 2450 |
) PAK3 siRNA (Human) |
||
| MBS8211190-15nmol | 15nmol | EUR 405 |
PAK3 siRNA (Human) |
||
| MBS8211190-30nmol | 30nmol | EUR 565 |
PAK3 siRNA (Human) |
||
| MBS8211190-5x30nmol | 5x30nmol | EUR 2450 |
) PAK4 siRNA (Mouse) |
||
| MBS8214565-15nmol | 15nmol | EUR 405 |
PAK4 siRNA (Mouse) |
||
| MBS8214565-30nmol | 30nmol | EUR 565 |
PAK4 siRNA (Mouse) |
||
| MBS8214565-5x30nmol | 5x30nmol | EUR 2450 |
 PAK2 Peptide |
||
| 3885P | 0.05 mg | EUR 197.7 |
|
Description: (CT) PAK2 peptide |
||
PAK2 Peptide |
||
| 3887P | 0.05 mg | EUR 197.7 |
|
Description: (NT) PAK2 peptide |
||
PAK2 Peptide |
||
| MBS151983-005mg | 0.05mg | EUR 175 |
PAK2 Peptide |
||
| MBS151983-5x005mg | 5x0.05mg | EUR 770 |
PAK2 Peptide |
||
| MBS152771-005mg | 0.05mg | EUR 175 |
PAK2 Peptide |
||
| MBS152771-5x005mg | 5x0.05mg | EUR 770 |
 PAK2 Antibody |
||
| 3885-002mg | 0.02 mg | EUR 206.18 |
|
Description: PAK2 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6, and are not activated by Cdc42/Rac binding. Of the six PAK proteins, only PAK2 is ubiquitously expressed and cleaved by caspase-3. This cleavage removes the amino-terminal regulatory domain and generates a constitutively active kinase fragment. Recent experiments have shown that following cleavage, the active fragment is myristoylated and directed to the plasma membrane and membrane ruffles where it promotes cell death via increased signaling through the c-Jun N-terminal kinase pathway, but without compromising mitochondrial integrity. |
||
PAK2 Antibody |
||
| 3885-01mg | 0.1 mg | EUR 523.7 |
|
Description: PAK2 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6, and are not activated by Cdc42/Rac binding. Of the six PAK proteins, only PAK2 is ubiquitously expressed and cleaved by caspase-3. This cleavage removes the amino-terminal regulatory domain and generates a constitutively active kinase fragment. Recent experiments have shown that following cleavage, the active fragment is myristoylated and directed to the plasma membrane and membrane ruffles where it promotes cell death via increased signaling through the c-Jun N-terminal kinase pathway, but without compromising mitochondrial integrity. |
||
PAK2 Antibody |
||
| 3887-002mg | 0.02 mg | EUR 206.18 |
|
Description: PAK2 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6, and are not activated by Cdc42/Rac binding. Of the six PAK proteins, only PAK2 is ubiquitously expressed and cleaved by caspase-3. This cleavage removes the amino-terminal regulatory domain and generates a constitutively active kinase fragment. Recent experiments have shown that following cleavage, the active fragment is myristoylated and directed to the plasma membrane and membrane ruffles where it promotes cell death via increased signaling through the c-Jun N-terminal kinase pathway, but without compromising mitochondrial integrity. |
||
PAK2 Antibody |
||
| 3887-01mg | 0.1 mg | EUR 523.7 |
|
Description: PAK2 Antibody: The p21-activated kinases (PAKs) are serine-threonine kinases that bind to the active forms of Cdc42 and Rac. They are divided into two groups, the first of which include PAK1, 2 and 3, and can be activated by Cdc42/Rac binding. Group 1 PAKs contain an autoinhibitory domain whose activity is regulated by Cdc42/Rac binding. The group 1 PAKs are known to be involved in cellular processes such as gene transcription, apoptosis, and cell morphology and motility. Much less is known about the second group, which includes PAK4, 5 and 6, and are not activated by Cdc42/Rac binding. Of the six PAK proteins, only PAK2 is ubiquitously expressed and cleaved by caspase-3. This cleavage removes the amino-terminal regulatory domain and generates a constitutively active kinase fragment. Recent experiments have shown that following cleavage, the active fragment is myristoylated and directed to the plasma membrane and membrane ruffles where it promotes cell death via increased signaling through the c-Jun N-terminal kinase pathway, but without compromising mitochondrial integrity. |
||
PAK2 Antibody |
||
| 35863 | 100ul | EUR 319 |
PAK2 Antibody |
||
| 35863-100ul | 100ul | EUR 302.4 |
PAK2 Antibody |
||
| 3443-100 | each | EUR 379.2 |